Top Markets
#1 Islamic Coin Islamic Coin +152.25%
#2 Bitway Bitway +40.84%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +38.17%
#4 Starpower Starpower +29.00%
#5 Pleasing Gold Pleasing Gold +28.64%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.29%
#7 Pons Pons +22.64%
#8 aelf aelf +18.42%
#9 Decred Decred +14.29%
#10 Venom Venom +14.02%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
AIkido Pharma Inc. AIkido Pharma Inc.

AIkido Pharma Inc.

AIKI
Rank in Stocks #30001
AIkido Pharma Inc., established in 1967 and headquartered in New York, New... AIkido Pharma Inc., established in 1967 and headquartered in New York, New York, is a biotechnology company primarily engaged in pioneering small-molecule anti-cancer treatments. The firm, which operated as Spherix Incorporated until its rebranding in March 2021, possesses a robust therapeutic pipeline addressing various malignancies, including prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. Key drug candidates in its development portfolio include DHA-dFdC, targeting pancreatic cancer, and KPC34, a small molecule designed for the treatment of both AML and acute lymphoblastic leukemia. Furthermore, AIkido Pharma Inc. is advancing an antiviral platform engineered to hinder the proliferation of numerous viruses, such as the influenza virus, Ebolavirus, Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. The company holds strategic license agreements with several academic and research institutions, including the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences.
Share Price
$3.56
Last synced: 2022-12-21
Market Cap
$18.70M
Change (1 day)
0.28%
Change (1 year)
0.00%
Country
US
Trade AIkido Pharma Inc. (AIKI)

Category

Healthcare
P/E ratio for AIkido Pharma Inc. (AIKI)
P/E ratio as of 2026 TTM: 0
According to AIkido Pharma Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for AIkido Pharma Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.